(Alliance News) - Hutchmed China Ltd on Tuesday said Chinese regulators have accepted and granted priority review to its new drug application for savolitinib to treat certain patients with advanced gastric cancer, marking another regulatory step forward for the targeted therapy. Read More
(Alliance News) - The FTSE 100 drifted lower on Wednesday in lacklustre trading ahead of the Christmas break, although a chunky disposal by BP brought some life to proceedings. Read More
(Alliance News) - Stock prices in London opened modestly lower on Wednesday, during a shortened trading session ahead of the Christmas holiday break. Read More
(Alliance News) - AstraZeneca PLC on Monday said a phase three trial in a potential treatment for a form of non-small cell lung cancer failed to meet a key aim, while its early breast cancer drug has been granted a breakthrough therapy designation in the US. Read More
(Alliance News) - Harbour Energy has struck a deal to deliver on a "long-standing ambition", while AstraZeneca reports a drug failed to meet its primary endpoint in a phase three trial, while another got breakthrough therapy designation in the US. Read More
(Alliance News) - Daiichi Sankyo Co Ltd on Thursday said the EU has validated an application for Datroway as a first-line treatment for patients with metastatic triple negative breast cancer who are not candidates for immunotherapy. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said its drug Saphnelo, or anifrolumab, has been approved in the European Union as a new pre-filled pen for systemic lupus erythematosus. Read More
(Alliance News) - AstraZeneca PLC on Monday said enhertu plus pertuzumab has been approved in the US as a first-line treatment of patients with HER2-positive metastatic breast cancer. Read More
(Alliance News) - Outgoing GSK PLC Chief Executive Officer Emma Walmsley has said the US is the best place to invest, in the latest blow to Britain's pharmaceutical sector, after a raft of drugs firms have scrapped or paused plans to invest in the UK. Read More
(Alliance News) - Hutchmed China Ltd on Monday said several of its oncology medicines will continue to be reimbursed under China's national insurance scheme next year, while one of its newer cancer drugs has secured a place on the country's first-ever commercial insurance drug list. Read More
(Alliance News) - The following London-listed shares received analyst recommendations on Monday morning and on Friday: Read More
(Alliance News) - A deal that gives the US zero tariffs on its imports of UK pharmaceuticals in return for the National Health Service raising spending on medicines will cost around GBP1 billion, Downing Street has said. Read More
(Alliance News) - AstraZeneca PLC on Tuesday announced that its new drug application under US Food & Drug Administration priority review for its selective inhibitor baxdrostat for certain patients has been accepted. Read More
(Alliance News) - AstraZeneca PLC on Tuesday announced that its new drug application under US Food & Drug Administration priority review for its selective inhibitor baxdrostat for certain patients has been accepted. Read More
(Alliance News) - The US on Monday exempted British pharmaceuticals from import tariffs under a unique deal which sees the UK increase spending on American drugs by 25%. Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it has appointed Jurriaan Dekkers as the company’s chief financial officer. Read More
(Alliance News) - A monthly injection could help people with severe asthma come off daily steroid tablets entirely without any impact on symptoms, a trial has found. Read More
(Alliance News) - Polar Capital Global Healthcare Trust PLC on Wednesday hailed "a very strong statement" in the result of its tender offer for shares, with nearly 80% of its shareholders choosing to stay invested. Read More
(Alliance News) - The US government on Tuesday announced cuts to the prices of 15 drugs through the Medicare health insurance system, including major discounts on the price of diabetes and weight loss drugs Wegovy and Ozempic. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said Imfinzi has been approved in the US as the first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers. Read More